1259. Bictegravir or Dolutegravir-Containing Antiretroviral Regimens in Solid Organ Transplantation: Single-Center Experience

Abstract Background Solid organ transplantation (SOT) is the definitive treatment for end-organ failure in HIV-positive recipients. Bictegravir (BIC) or dolutegravir (DTG) based antiretroviral therapy (ART) preferred ART due to high efficacy, excellent tolerability and minimal drug interactions, yet there a paucity of data on these second generation integrase inhibitors (INSTIs) SOT. We report Memorial Transplant Institute’s experience using INSTI-containing with without emtricitabine/tenofovir alafenamide (FTC/TAF) persons HIV. Table 1.Demographics clinical features 16 patients HIV undergoing solid (SOT).3TC: lamivudine; AA: African American; BIC: bictegravir; DTG: dolutegravir; F: female; FTC: emtricitabine; H: Hispanic/Latino/a/x; IN: integrase; M: male; NH: Non-Hispanic/Latino/a/x; PR: protease; RPV: rilpivirine; RT: reverse transcriptase; SOT: transplantation; TAF: tenofovir alafenamide; W: whiteTable 2.Clinical course 8 after ABC: abacavir; ART: therapy; ATV: atazanavir; c: cobicistat; DRV: darunavir; eFGR: estimated glomerular filtration rate; ETR: etravirine; r: ritonavir; RAL: raltegravir; RTV: Methods This single-center observational study compiles from medical records all SOT seen by Division Infectious Disease January 2017 through April 2022. information management candidates recipients our center. Results Sixteen met inclusion criteria: (7 kidney, 1 heart) (all kidney). Demographics are presented 1. Patients were 63% male mean age 55 years, CD4 323 cells/mm3, living years. regimens BIC/FTC/TAF (50%), DTG/rilpivirine (RPV) (19%), DTG + FTC/TAF (19%) RPV/FTC/TAF (6%), DTG/lamivudine (6%). All pharmacokinetic enhancers discontinued avoid interactions anti-rejection medications. Last on-treatment RNA was < 200 copies/mL 100% patients. The post-renal transplant 2. most common post-SOT regimen BIC/FTC/TAF. Post-SOT maintained copies/mL. No ART-related adverse effects documented. Two allograft- life-threatening infections one episode acute antibody rejection reported. Expectedly, serum creatinine decreased rate increased transplant. Conclusion provide additional insight into use BIC- DTG-containing peri-SOT period. Our growing suggests effective well tolerated following kidney transplantation. Additional research INSTIs patient population needed. Disclosures Authors: reported disclosures.